Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 16

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 16
---
 — |   |
| Net loss attributable to common stockholders                                                |     | $                                              |    (63,102 | ) |     | $    |    (6,275 | ) |     | $                |    (10,177 | ) |     | $    |   (43,850 | ) |
| Net loss per share, basic and diluted                                                       |     | $                                              |      (6.20 | ) |     | $    |     (0.78 | ) |     | $                |      (1.02 | ) |     | $    |     (4.40 | ) |
| Weighted average shares outstanding used in calculating net loss per share, basic and       
 diluted                                                                                     |     |                                                | 10,175,580 |   |     |      | 8,011,802 |   |     |                  | 10,023,891 |   |     |      | 9,972,771 |   |
| Pro forma net loss per share, basic and diluted (unaudited)(1)                              |     | $                                              |            |   |     |      |           |   |     | $                |            |   |     |      |           |   |
| Pro forma weighted average shares outstanding used in calculating net loss per share, basic 
 and diluted (unaudited)(1)                                                                  |     |                                                |            |   |     |      |           |   |     |                  |            |   |     |      |           |   |

| (1) | The unaudited basic and diluted pro forma net loss per share were computed using the weighted-average shares |

10

| of common stock outstanding, including the pro forma effect of the conversion of all outstanding redeemable convertible preferred stock into shares of common stock. Pro forma basic and diluted 
 net loss per share does not include the shares expected to be sold in this offering.                                                                                                             |

|                                        |     | As of June 30, 2025 |          |   |     |              |     |                |
|:---------------------------------------|:----|:--------------------|---------:|:--|:----|:-------------|:----|:---------------|
|                                        |     | Actual              |          |   |     | Pro Forma(1) |     | Pro Forma As   
 Adjusted(2)(3) |
|                                        |     | -in thousands       |          |   |     |              |     |                |